Annual report pursuant to Section 13 and 15(d)

Non-Controlling Interests (Tables)

v3.21.1
Non-Controlling Interests (Tables)
12 Months Ended
Dec. 31, 2020
Non-Controlling Interests  
Schedule of Non-Controlling Interests in Consolidated Entities

Non-controlling interests in consolidated entities are as follows:

    

    

For the year ended

    

    

    

    

 

As of December 31, 2020

December 31, 2020

As of December 31, 2020

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

Acquisition Corp VIII

$

(7)

$

(27)

$

(34)

 

10.0

%

Aevitas

(2,370)

 

(823)

 

(3,193)

 

39.0

%

Avenue 2

 

5,800

 

(3,974)

 

1,826

 

77.4

%

Baergic

 

(1,662)

 

(97)

 

(1,759)

 

39.5

%

Cellvation

 

(1,089)

 

(182)

 

(1,271)

 

22.1

%

Checkpoint 1

 

41,704

 

(13,265)

 

28,439

 

80.4

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

567

 

(1,478)

 

(911)

 

30.5

%

Helocyte

 

(4,986)

 

(259)

 

(5,245)

 

18.8

%

JMC

 

138

 

491

 

629

 

7.1

%

Mustang 2

 

116,060

 

(36,429)

 

79,631

 

80.9

%

Oncogenuity

(82)

 

(376)

 

(458)

 

25.3

%

Tamid

 

(663)

 

(40)

 

(703)

 

22.8

%

Total

$

153,120

$

(56,459)

$

96,661

 

  

    

For the year ended

    

    

 

As of December 31, 2019

December 31, 2019

As of December 31, 2019

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

Aevitas

$

(1,249)

$

(694)

$

(1,943)

 

35.8

%

Avenue 2

 

24,269

 

(19,011)

 

5,258

 

77.3

%

Baergic

 

23

 

(1,162)

 

(1,139)

 

33.0

%

Cellvation

 

(732)

 

(158)

 

(890)

 

20.6

%

Checkpoint 1

 

29,389

 

(14,687)

 

14,702

 

78.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(320)

 

(99)

 

(419)

 

10.6

%

Helocyte

 

(4,322)

 

(402)

 

(4,724)

 

19.3

%

JMC

 

(211)

 

325

 

114

 

6.9

%

Mustang 2

 

62,025

 

(25,727)

 

36,298

 

70.3

%

Tamid

 

(565)

 

(85)

 

(650)

 

22.8

%

Total

$

108,017

$

(61,700)

$

46,317

 

Note 1:  Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:  Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.